DA-EPOCH±R方案与ESHAP±R方案治疗复发难治性弥漫大B细胞淋巴瘤效果比较

Efficacy of DA-EPOCH±R regimen and ESHAP±R regimen in treatment of relapsed or refractory diffuse large B-cell lymphoma

目的:对比DA-EPOCH±R方案与ESHAP±R方案治疗复发难治性弥漫大B细胞淋巴瘤(DLBCL)的疗效及不良反应。方法:161例复发难治性DLBCL患者中83例接受DA-EPOCH±R方案化疗4~6个周期,78例患者接受ESHAP±R方案化疗4~6个周期,比较两组疗效及不良反应。结果:DA-EPOCH±R组的总有效率优于ESHAP±R组(P=0.036),两组间各项不良反应的发生率比较差异均无统计学意义(P>0.05)。DA-EPOCH±R组中位无进展生存期和总生存期均长于ESHAP±R组(P<0.05)。结论:DA-EPOCH±R方案治疗复发难治性DLBCL的临床疗效优于ESHAP±R方案,且不良反应发生率相当。

Aim:To compare the efficacy and adverse reaction of DA-EPOCH±R regimen and ESHAP±R regimen in treatment of patients with relapsed or refractory diffuse large B-cell lymphoma(R/R DLBCL).Methods:A total of 161 R/R DLBCL patients were retrospectively analyzed,among them,83 were treated with DA-EPOCH±R regimen for 4 to 6 cycles and 78 were treated with ESHAP±R regimen for 4 to 6 cycles.The efficacy and adverse reaction of two groups were compared.Results:The ORR of the DA-EPOCH±R group was superior than that of the ESHAP±R group(P=0.036).The adverse reaction rates were similar in the DA-EPOCH±R group and ESHAP±R group(P>0.05).The median PFS and OS were longer in the DA-EPOCH±R group than those in the ESHAP±R group(P<0.05).Conclusion:In treatment of R/R DLBCL,the efficacy of DA-EPOCH±R regimen is better than ESHAP±R regimen with similar rates of the adverse reactions.